Ibogaine in Arizona

Which law actually funds Arizona’s ibogaine study

Almost every account of Arizona’s programme credits House Bill 2871. That bill did not become law.

HB 2871, sponsored by Representative Justin Wilmeth of Phoenix, passed the House with bipartisan support in March 2025 and then died in the Senate. The money was enacted instead through SB 1735, the FY2026 general appropriations act, whose own summary carries the line item: Ibogaine Clinical Research Grants, General Fund, non-lapsing, $5,000,000.

The appropriation is non-lapsing, which means it does not expire at the end of the fiscal year. For a clinical study that will take years to design and run, that matters more than the headline figure. The Arizona Department of Health Services administers the money as a grant to a single research institution.

The conditions on the grant

SB 1735 attaches three conditions, and the Department of Health Services carried all three into its grant solicitation. The recipient must have a proven history of research and treatment in neurological disease, must operate a neurosurgery programme with the requisite clinical and research facilities staffed by professionals with expertise in the most challenging neurological and neurosurgical conditions, and must demonstrate the ability to facilitate pioneering research and innovation in the diagnosis and treatment of neurological conditions.

There is no matching-funds requirement in Arizona’s law. HB 2871, as amended, would have required at least $5 million in matching money from non-state sources, and that condition is repeated everywhere as though it were binding. It died with the bill, and we repeated it here ourselves. What exists instead is a private undertaking. According to the Arizona House’s own announcement, former US Senator Kyrsten Sinema, who testified before the House Appropriations Committee in support of HB 2871, “has pledged to raise $5 million in private funding to match the state’s investment and ensure the study moves forward”. A pledge is not a condition, and nothing in SB 1735 makes the state’s money contingent on it.

Who won the grant, and when a result might arrive

Applications opened on 3 October 2025 and closed on 19 November. On 5 August 2026 the department awarded the $5 million to Barrow Neurological Institute in Phoenix, for a Phase 1/2 double-blind, placebo-controlled trial in 40 adults living with chronic symptoms after traumatic brain injury, run with the Barrow Neuro Analytics Center and Arizona State University. Half will receive ibogaine and half placebo. Barrow expects to enrol its first participant in 2027. Hold that date against the appropriation: Arizona voted the money in June 2025, the first participant will be dosed more than eighteen months later, and a Phase 1/2 result follows years after that. Nothing about that timetable is unusual for drug development. It is only unusual against the way state ibogaine funding gets reported.

What the appropriation does not do

Nothing in Arizona’s appropriation touches the legal status of ibogaine.

A state cannot reschedule a federally controlled substance. Possession remains a federal offence in Arizona, no physician may prescribe it, and no clinic may lawfully administer it outside an approved research protocol. The appropriation buys a study inside the federal system; it does not create an exception to it.

Why veterans are at the centre of it

The Arizona bill, like most of the state legislation that followed, was argued on veterans’ mental health rather than on addiction or on drug policy.

That framing is doing real political work. It moved a psychedelic appropriation through a legislature that had shown no appetite for psychedelics as such, and it has been repeated in Texas, Kentucky, Missouri, New York and elsewhere. The Stanford observational study of special-operations veterans with traumatic brain injury, published in Nature Medicine in 2024, is the evidence most often cited in support. It followed thirty veterans treated with magnesium-ibogaine in Mexico, assessed before and after.

It is worth holding two things at once. The veterans’ case is genuine, the existing treatment options for TBI are poor, and the observational results are striking. And an observational cohort treated abroad is not a controlled trial, which is precisely why appropriating money for one is a reasonable response and declaring the question settled is not.

Arizona in context

Arizona was the second state to appropriate public money for ibogaine research, after Texas earlier the same month, and one of only three to have committed money at all. Its $5 million is a tenth of what Texas put up and it is the only state grant awarded to a single named institution rather than to a university consortium. The federal position carries the full comparison, state by state.

Colorado is the only state to have gone further than research funding, having decriminalised personal possession by ballot measure in 2022. The federal position explains why that is the outer limit of what any state can do, and the status by country table sets out the regimes available elsewhere.